Atanas G. Atanasov is Chair of Pharmacology and Research Leader at Patient Safety & Digital Health (PaDiH) Group (Danube Private University) and at Ludwig Boltzmann Institute Digital Health and Patient Safety (LBI-DHPS, Medical University of Vienna), Professor of IGAB PAS, Honorary Fellow of the International Lipid Expert Panel (ILEP) and of the Saveetha Institute of Medical and Technical Sciences (SIMATS), and Editor-in-Chief of CurrentResearch in Biotechnology (#CRBIOTECH, Elsevier), of Exploration of Digital Health Technologies (#ExplorDHT, Open Exploration), and of Biology Research and Life Sciences section of Sci (MDPI).
Dr Atanasov holds MSc in Biotechnology (from the University of Sofia, Bulgaria), PhD in Biochemistry (from the University of Bern, Switzerland), and Habilitation (Dr. habil. / PD) in Pharmaceutical Biology (from the University of Vienna, Austria). He has authored >350 publications across Molecular Medicine, Public Health, Digital Health Technologies, Biotechnology, Natural Products, Nutrition, Science Communication, Innovation, and Molecular Pharmacology.
Recognized as a Cross-Field Highly Cited Researcher (Clarivate, 2021-2023), and listed among the World’s Top 2% Scientists (since 2020, Stanford University/Scopus/Elsevier data, 2025), Dr. Atanasov is also a a distinguished promoter of digital science communication (including use of social media, e.g., a >120 000-followers X (formerly Twitter), >35 000-followers LinkedIn, and >10 000-followers Bluesky channels) and open innovation (e.g., through the executive leadership of global open innovation platforms focused on Digital Health and Patient Safety (#DHPSP) and on Natural Product Research (#INPST)).
Beyond his academic and editorial roles, Dr. Atanasov undertakes selective strategic advisory roles and contributes as an expert consultant and keynote speaker in molecular medicine, science communication, nutraceuticals, biotechnology, digital health, and innovation. In these capacities, he supports organizations, publishers, institutions, expert panels, and international forums in advancing evidence-based products, strategies, and high-impact public engagement initiatives.